Browse > Article

Inhibitory Effects of YP 12, A Newly Synthesized Obovatol Derivative on Rat Aortic Vascular Smooth Muscle Cell Proliferation  

Lim, Yong (Department of Clinical Laboratory Science, Dong-eui Univerisity)
Lee, Mi-Yea (Department of Social Welfare, World Cyber College)
Jung, Jae-Kyung (College of Pharmacy, Chungbuk National University)
Pyo, Myoung-Yun (College of Pharmacy, Sookmyung Women's University)
Yun, Yeo-Pyo (College of Pharmacy, Chungbuk National University)
Publication Information
Journal of Food Hygiene and Safety / v.26, no.3, 2011 , pp. 187-191 More about this Journal
Abstract
Platelet derived growth factor (PDGF)-BB is one of the most potent vascular smooth muscle cell(VSMC) proliferative factors, and abnormal VSMC proliferation by PDGF-BB plays an important role in the development and progression of atherosclerosis. The aim of this study was to assess the effect of YP 12, a newly synthesized obovatol derivative, on the proliferation of PDGF-BB-stimulated rat aortic VSMCs. The anti-proliferative effects of YP 12 on rat aortic VSMCs were examined by direct cell counting and by using $[^3H]$ thymidine incorporation assays. It was found that YP 12 potently inhibited the growth of VSMCs. The pre-incubation of YP 12 (1-4 ${\mu}M$) significantly inhibited the proliferation and DNA synthesis of 25 ng/ml PDGF-BB-stimulated rat aortic VSMCs in a concentration-dependent manner. In accordance with these findings, YP 12 revealed blocking of the PDGF-BB-inducible progression through G0/G1 to S phase of the cell cycle in synchronized cells. Whereas, YP 12 did not show any cytotoxicity in rat aortic VSMCs in this experimental condition by WST-1 assay. These results also show that YP 12 may have potential as an anti-proliferative agent for the treatment of restenosis and atherosclerosis.
Keywords
Atherosclerosis; proliferation; vascular smooth muscle cell; PDGF-BB;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Jung, F., Haendeler, J., Goebel, C., Zeiher, A. M., & Dimmeler, S. (2000). Growth factor-induced phosphoinositide 3-OH kinase/ Akt phosphorylation in smooth muscle cells: induction of cell proliferation and inhibition of cell death. Cardiovasc Res, 48(1), 148-157.   DOI   ScienceOn
2 Lee, M. S., Yang, J. E., Choi, E. H., In, J. K., Lee, S. Y., Lee, H., et al. (2007). Synthesis of obovatol derivatives and their preliminary evaluation as antitumor agents. Bull Korean Chem Soc, 28(9), 1601-1604.   DOI
3 Lee, S. K., Kim, H. N., Kang, Y. R., Lee, C. W., Kim, H. M., Han, D. C., et al. (2008). Obovatol inhibits colorectal cancer growth by inhibiting tumor cell proliferation and inducing apoptosis. Bioorg Med Chem, 16(18), 8397-8402.   DOI   ScienceOn
4 Lim, Y., Kwon, J. S., Kim, D. W., Lee, S. H., Park, R. K., Lee, J. J., et al. (2010). Obovatol from Magnolia obovata inhibits vascular smooth muscle cell proliferation and intimal hyperplasia by inducing p21Cip1. Atherosclerosis, 210(2), 372-380.   DOI   ScienceOn
5 Majesky, M. W., Reidy, M. A., Bowen-Pope, D. F., Hart, C. E., Wilcox, J. N., & Schwartz, S. M. (1990). PDGF ligand and receptor gene expression during repair of arterial injury. J Cell Biol, 111(5 Pt 1), 2149-2158.
6 Mulvany, M. J. (1990). Structure and function of small arteries in hypertension. J Hypertens Suppl, 8(7), S225-232.
7 Ross, R. (1990). Mechanisms of atherosclerosis--a review. Adv Nephrol Necker Hosp, 19, 79-86.
8 Ross, R. (1993). The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature, 362(6423), 801-809.   DOI   ScienceOn
9 Ross, R. (1995). Cell biology of atherosclerosis. Annu Rev Physiol, 57, 791-804.   DOI   ScienceOn
10 Ross, R. (1999). Atherosclerosis--an inflammatory disease. N Engl J Med, 340(2), 115-126.   DOI   ScienceOn
11 Bornfeldt, K. E., Raines, E. W., Graves, L. M., Skinner, M. P., Krebs, E. G., & Ross, R. (1995). Platelet-derived growth factor. Distinct signal transduction pathways associated with migration versus proliferation. Ann N Y Acad Sci, 766, 416-430.   DOI
12 Braun-Dullaeus, R. C., Mann, M. J., & Dzau, V. J. (1998). Cell cycle progression: new therapeutic target for vascular proliferative disease. Circulation, 98(1), 82-89.   DOI   ScienceOn
13 Erlinge, D. (1998). Extracellular ATP: a growth factor for vascular smooth muscle cells. Gen Pharmacol, 31(1), 1-8.   DOI   ScienceOn
14 Chamley, J. H., Campbell, G. R., McConnell, J. D., & Groschel- Stewart, U. (1977). Comparison of vascular smooth muscle cells from adult human, monkey and rabbit in primary culture and in subculture. Cell Tissue Res, 177(4), 503-522.
15 Claesson-Welsh, L. (1994). Platelet-derived growth factor receptor signals. J Biol Chem, 269(51), 32023-32026.
16 Dzau, V. J., Braun-Dullaeus, R. C., & Sedding, D. G. (2002). Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat Med, 8(11), 1249-1256.   DOI   ScienceOn
17 Fang, F., & Newport, J. W. (1991). Evidence that the G1-S and G2-M transitions are controlled by different cdc2 proteins in higher eukaryotes. Cell, 66(4), 731-742.   DOI   ScienceOn
18 Stroobant, P., & Waterfield, M. D. (1984). Purification and properties of porcine platelet-derived growth factor. EMBO J, 3(12), 2963-2967.
19 Sachinidis, A., Locher, R., Vetter, W., Tatje, D., & Hoppe, J. (1990). Different effects of platelet-derived growth factor isoforms on rat vascular smooth muscle cells. J Biol Chem, 265(18), 10238-10243.